Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion.Austin, United States, March 19, 2026 (GLOBE NEWSWIRE) -- ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the penny stocks with potential to rise 1000 percent. Allogene ...
Mycophenolate mofetil is associated with comparable treatment outcomes to methotrexate among patients with juvenile localized ...
You won’t want to miss The Scleroderma Awareness Open: Pickleball with a Purpose on the Wauwatosa Patch calendar ...
Spotted on the Waukesha calendar: The Scleroderma Awareness Open: Pickleball with a Purpose ...
If you grew up calling them "Uncle Jesse" and "Stephanie," this duo says it's time for a cancer prevention conversation.
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S.FDA expressed openness to an alternative ...
Atomic force microscopy (BioAFM) drives innovation in cosmetics and healthcare, ensuring product efficacy through precise ...
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a ...
Gilead Sciences has built up its position in the hot area of T-cell engagers (TCEs) for autoimmune diseases with an agreement ...
Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the ...
The Philadelphia hospital treats complex cases and expands access to transplant care for patients who may not qualify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results